Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | LDHB | P07195 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 4/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081107 | 0.82 | KDM4E (0.41) | LDHALDHBKDM4EMAPTRAB9A | |
| SCHEMBL6080260 | 0.82 | KDM4E (0.34) | LDHALDHBKDM4EMAPTRAB9A | |
| SCHEMBL6079524 | 0.82 | TDP1 (0.44) | LDHALDHBKDM4EMAPTRAB9A | |
| SCHEMBL6079860 | 0.80 | CTSB (0.41) | PIN1MAPT | |
| SCHEMBL6080024 | 0.80 | CYP3A4 (0.38) | PIN1KDM4EMAPTRAB9ATDP1 | |
| SCHEMBL6079736 | 0.80 | DHODH (0.38) | KDM4EMAPTRAB9ATDP1 | |
| SCHEMBL6079184 | 0.77 | PIN1 (0.34) | PIN1F11 | |
| SCHEMBL6080431 | 0.76 | DHODH (0.40) | PIN1KDM4EMAPT | |
| SCHEMBL6080278 | 0.74 | PIN1 (0.33) | PIN1F11 | |
| SCHEMBL6080504 | 0.74 | XDH (0.34) | SLC22A12KDM4EMAPTRAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | PIN1 3446/4885TTR 3586/4885ALB 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.